Surzebiclimab, the innovative monoclonal antibody, appears to be an exciting development in treating autoimmune disease. This drug inhibits the IL-17 receptor A, a key factor that plays a role in immune responses https://surzebiclimab-therapeuti177062.wikicorrespondence.com/user